Premium
Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance
Author(s) -
Fiorentino Teresa Vanessa,
Succurro Elena,
Sciacqua Angela,
Andreozzi Francesco,
Perticone Francesco,
Sesti Giorgio
Publication year - 2020
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.3333
Subject(s) - prediabetes , medicine , fatty liver , type 2 diabetes , diabetes mellitus , coronary artery disease , disease , gastroenterology , impaired glucose tolerance , impaired fasting glucose , population , endocrinology , environmental health
Abstarct Introduction Non‐alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD) in patients with type 2 diabetes; nonetheless, it is unknown whether the relationship between NAFLD and CVD occurs also in subjects with prediabetes. Herein, we evaluated whether NAFLD is associated with prevalent CVD in subjects with different glucose tolerance states independently of cardiovascular risk factors. Materials and methods Presence of NALFD, defined by liver ultrasound, and its association with prevalent composite and individual CVD, including coronary artery disease (CAD) and cerebrovascular disease, was assessed in a cohort of 1254 Caucasian subjects classified as having normal glucose tolerance (NGT, n = 517), prediabetes (n = 397) or type 2 diabetes (n = 340). Results Prevalence of NAFLD in the study population was 47.9%. Presence of NAFLD was linked to an augmented prevalence of composite CVD and individual CAD in all the three glucose tolerance groups. In a logistic regression model adjusted for several cardio‐metabolic risk factors, subjects with NGT and NAFLD exhibited a 3.2‐ and 3.4‐fold increased risk of having CVD or CAD, respectively, as compared with those without NAFLD. Similarly, subjects with prediabetes and NAFLD showed an increased risk of having CVD or CAD by 2.3‐ and 2.0‐fold, respectively, in comparison to their counterpart without NAFLD. Within the group with type 2 diabetes, subjects having NAFLD displayed a 2.3‐ and 2.0‐fold higher risk of having CVD or CAD, respectively, in comparison to those without NAFLD. Conclusion Ultrasonography‐defined NAFLD is independently associated with an increased risk of having CVD in individuals with different glucose tolerance.